Pattern recognition electrodes are arranged in a cuff used for the early, pre-definitive stage of a pattern recognition fitting in tasks such as controls evaluation and pattern recognition practice. Photograph courtesy of IBT.
Infinite Biomedical Technologies (IBT), Baltimore, has received approval from the U. S. Food and Drug Administration (FDA) for its Sense myoelectric prosthetic control system to be sold in the United States. Sense uses a pattern recognition algorithm to control prosthetic devices. It is the second prosthetic control system to receive FDA approval, after Coapt’s Complete Control was approved in May 2017.
IBT CEO Rahul Kaliki told Wired that he expects Sense to be available in the U.S. market by the end of November. The company began offering the control system in Europe in November 2017.
For more information about pattern recognition systems, including the Sense control system, visit “Upper-limb Prosthetics: Pattern Recognition Shows Practical Promise” from the September issue of The O&P EDGE.
